Condensed abstract:
A population-based sample of women diagnosed with invasive, unilateral breast cancer was prospectively assessed for lymphedema, upper-body symptoms and vital status for a median of 6.6 years, to evaluate the relationship between lymphedema and survival. Approximately 45% of women had at least one upper-body symptom at 6.6 years post-diagnosis, while 34% had clinical evidence of lymphedema. A total of 27 (9.4%) women died during the follow-up period, and clinically evident lymphedema predicted mortality (HR=3.0; 95% CI: 1.1, 8.7, p=0.04). These findings suggest that lymphedema may influence breast cancer survival and warrant further investigation and explication of a potential underlying biology.
Introduction
In Westernised countries, secondary lymphedema (characterised by regional swelling, typically of an extremity) presents mostly following treatment for cancer 1 , in particular breast, genitourinary and gynaecological cancers and melanoma. While 5-year overall survival rates following such cancers generally exceed 80% 2 , treatment-associated morbidity is common and persists well beyond the active treatment period [3] [4] . Specifically, lymphedema develops in approximately one-fifth of these cancer survivors 5 , with incidence increasing over time.
Lymphedema presents when the demand for lymphatic drainage exceeds the capacity of lymphatic circulation 6 . This may occur as a consequence of tumor-induced neo-F o r P e e r R e v i e w (including lymphocytes, monocytes, and dendritic cells), limiting the capacity of the immune system to eliminate cancer antigens. In particular, defects on dendritic cells, key cells in the presentation of antigen, have been well characterised in patients with breast cancer and may be responsible for the late appearance of distal disease following mastectomy 9 . Indeed, local immune deficiency derived from lymphedema may explain the increased risk of infection observed among those with lymphedema 10 . Furthermore, metastases (and by inference, survival) may then be a further consequence of immune deficiency and are clearly a prime concern for cancer patients and their clinicians. Yet, with the exception of the work regarding Stewart-Treves syndrome 11 , the relationship between lymphedema following cancer and survival has, to date, not been evaluated.
As a follow-up to the Pulling Through Study, our longitudinal, population-based, cohort study designed to track the physical and psychosocial concerns, including lymphedema, of women six to 18 months after breast cancer diagnosis 4 , we recontacted women approximately five years later. The purposes of this follow-up work were: 1) to determine the prevalence of upper-body symptoms and lymphedema at six years following breast cancer; 2) to estimate the 6-year cumulative burden of lymphedema; and 3) to examine the prognostic significance of lymphedema with respect to overall 6-year survival (OS).
Methods and Materials

Study design and sample recruitment of the original 'Pulling Through Study'
Following ethical approval, 511 women diagnosed in 2002 with a first, primary, invasive, unilateral breast cancer, aged 74 years or younger, and residing within 100 kilometres (i.e., 62 miles) of Brisbane, Australia, were randomly selected from the Queensland Cancer Registry.
Younger women (<50 years) were over-sampled 1.3-fold to ensure adequate numbers for specific age-group analyses. Thirty-five women were subsequently deemed ineligible. Doctor F o r P e e r R e v i e w consent was obtained for 88% (n=417), and of these, informed consent was obtained for 68%
(287 women or 60% of those potentially eligible). Participation involved a clinical assessment and/or completion of a self-administered questionnaire every three months between six and 18 months post-diagnosis.
At baseline assessment (6 months post-diagnosis), study participants completed a mailed, self-administered questionnaire on a range of demographic, treatment and general health characteristics. Lymphedema status was evaluated in the clinic using two objective measures, bioimpedance spectroscopy (BIS) and sum of arm circumferences (SOAC), and in the questionnaire by subjective account of self-reported arm swelling. Tumour characteristics were abstracted from histopathology reports at the Queensland Cancer Registry. Full details of the study design, outcome measures and subsequent results have been published previously 4 . Of relevance to this paper, approximately one-third of women participated on a questionnaire-only basis; hence they lack objective assessments of lymphedema and are omitted from survival analyses related to those outcomes.
Design and sample recruitment of the 'Pulling Through Study: A follow up'
The follow-up study reported here commenced approximately six years following the date of breast cancer diagnosis for those in the original 'Pulling Through Study'. Of the 287 original participants, 11 withdrew from the study and were therefore not recontacted. The records of the remaining 276 women were cross-referenced with the mortality database at the Institutional ethical approval was sought and approved for all aspects of recruitment and study implementation. Participants were followed until 15 April 2009 when a second search of the mortality registry was undertaken to determine vital status of all 287 original participants of the Pulling Through Study; therefore, irrespective of participation in the 6-year follow-up study, all observations not previously ended were censored at this date.
Data collection
The questionnaire was designed to collect information on the presence of upper-body symptoms and self-reported arm swelling, using the same questions as in the original study described elsewhere 4, 12 . In summary, using items from the Functional Assessment of Cancer Therapy -Breast (FACT-B+4) questionnaire 13 , as well as the Disability of the Arm, Shoulder and Hand (DASH) questionnaire 14 , information was collected on the presence of stiffness, pain, weakness, poor range of motion, tingling and numbness on the affected side, and severity was rated using a 5-point Likert scale. Women were also asked whether they had experienced arm swelling in the past 12 months.
For our objective assessment of lymphedema, BIS measurements were taken on each arm using a SEAC SFB7 monitor (SEAC Australia, Impedimed, Brisbane, Australia). The impedance of the extracellular fluid for each limb was measured using the manufacturer's software, to compute the ratio of impedance values, comparing the treated and untreated sides. A participant was classified as having lymphedema when the impedance ratio was more than three standard deviations above normative data, with the side of dominance taken into account (also coincides with an L-DEX score of greater than 10) [15] [16] . During the original Pulling Through Study, lymphedema also was measured using the sum of arm circumference 
Statistical analysis
Proportions of those reporting moderate to extreme upper-body symptoms at six years postdiagnosis were calculated and compared with 6-month post-diagnosis data. Point prevalence of lymphedema according to BIS and self-report were also calculated at six years postdiagnosis. Cumulative burden, representing the proportion of the sample that experienced lymphedema at any stage from six months to six years after diagnosis, was calculated using data collected via self-report and BIS; since circumferences were not measured at the 6-year follow-up, lymphedema status based on SOAC is not available.
The absolute difference in mortality between the two groups was calculated ([number of deaths in lymphedema group/number in lymphedema group] -[number of deaths in no lymphedema group/number in no lymphedema group]). Mean survival times were calculated using the Kaplan-Meier method and differences between groups (lymphedema status: no/yes)
were assessed using the Log-rank test. Cox proportional hazards regression models were utilised to estimate the hazard ratio (HR) and 95% confidence intervals (CIs) for the association between lymphedema status (as defined by cumulative burden between 6 and 18 months post-diagnosis) and overall 6-year survival (OS). Due to limited statistical power, bivariate model estimates were adjusted, one at a time, for known markers of breast cancer prognosis. All analyses were performed using SPSS version 16.
Results
Characteristics of the study participants
As indicated earlier, our first death search had shown that sixteen of the original cohort had F o r P e e r R e v i e w died prior to this follow-up study, leaving 260 potential participants in the follow-up study. Of these, 22 (8.5%) were lost to follow-up, 36 (13.8%) refused to participate and 7 women had passed away. The remaining 195 (75%) women provided consent, and of these, 94% (n=183) returned the questionnaires and 85% (n=166) had BIS measures taken. Four additional women died between time of the 6-year follow-up assessment (two participants and two previously lost-to-follow-up) and the final death search, making a total of 27 deaths from the original cohort of 287.
Demographic and disease characteristics of the 158 women with complete outcome data (BIS and self-reported assessment of lymphedema) from the follow-up study were similar to the original Pulling Through Study cohort (n=287) ( Table 1 ). The additional 25 women with questionnaire information only (n=183) did not alter this profile (data not shown). Similarly, the characteristics of the 190 women with sufficient data to determine cumulative burden of lymphedema between 6-18 months post-diagnosis, and therefore included in the survival analyses, were comparable to the initial research sample (Table 1) . Of note, the original cohort was shown to be representative of the wider Queensland breast cancer population 4 .
F o r P e e r R e v i e w months following breast cancer diagnosis and the follow-up study. This was, in part, due to somewhat lower prevalences reported at baseline by the participants in the follow-up study and, in part, due to modest but real declines in the proportions of women reporting symptoms.
Numbness was the single symptom reported most frequently at both time points (29.2% at 6 months and 15.6% at 6 years post-diagnosis), despite a reduction of almost 50% in prevalence.
Using BIS, point prevalence of lymphedema at the 6-year follow-up was 6.5% (95% CI: 3.6, 10.6), by which time 34% (95% CI: 28.3, 40.2) of women showed evidence of the condition at one or more testing phases. Two new cases of lymphedema were identified for the first time at the last assessment, for an incidence rate of 1.2% (95% CI: 0.3, 4.3) between 18 months and 6 years following breast cancer diagnosis.
The prevalence of self-reported arm swelling at the 6-year follow-up was 22% (95% CI: 16.0, 29.6), and the incidence between 18 months and 6 years post-diagnosis was 6% (95% CI: 3.4, 10.4) based on 11 women not previously reporting arm swelling during the original study.
Consequently, 48.2% (95% CI: 43.0, 53.5) of the sample experienced arm swelling at some point during the 6-year follow-up period.
Lymphedema and overall survival
The 6-year absolute mortality was 12.9% and 14.6% among those with lymphedema diagnosed by BIS or SOAC, respectively, compared to 5.5% and 5.2% for those without lymphedema based on BIS or SOAC. Absolute differences between the two groups therefore were 7-9%, depending on the measure used. Those with evidence of lymphedema between 6-18 months following diagnosis survived for a mean of 79-82 months compared to 85 months among those without clinical evidence of the condition (BIS, p=0.07; SOAC, p=0.03). Unadjusted Cox proportional hazards models estimated that the risk of death was increased 2-3 fold among women with objective evidence of lymphedema between 6-18 months postdiagnosis ( did not self-report arm swelling between 6-18 months were similar, and the HR was not significantly different than 1.0 (Table 3) .
Conclusions
Upper-body morbidity following breast cancer is common, may persist well beyond the active The adverse consequences of having lymphedema are well-documented, with presence of the condition having a profound effect on all aspects of quality of life 3, 20 . However, this study is the first, to our knowledge, to evaluate the potential impact of lymphedema on survival.
Results provide positive, albeit preliminary, evidence that lymphedema may be an important prognostic factor, associated with a 2-3-fold increased risk of death during the 6 years following breast cancer diagnosis. Further, the observed relationship between lymphedema and poorer survival may be independent of other recognized indicators of disease severity and outcome, because it was not explained away by adjustment for factors such as original disease status, extensiveness of treatment, or other personal characteristics. Whether or not the relationship reflects a direct effect of lymphedema on mortality among women with breast cancer, the possibility of lymphedema as a marker of undetected malignant disease, and/or that women predisposed to develop lymphedema are more susceptible to further immune- tumour-draining lymph nodes compared with healthy lymph nodes 24 , providing further evidence for a potential explanation of our findings. Clearly more research into the biology potentially underlying a relationship between lymphedema and breast cancer mortality is needed and now can be more readily studied with recently developed techniques 24 .
In contrast to findings derived from clinical assessment and objective measurement of lymphedema, there was no relationship between lymphedema based on self-reported arm swelling and survival. This may be because there is, in fact, no relationship. Alternatively, it may be that self-reported arm swelling is not an accurate measure of lymphedema. Previous work using this same dataset demonstrated that self-report of upper-body symptoms, including swelling, is common among those with and those without objective evidence of lymphodema 3 . Further, while presence of self-reported symptoms is associated with lymphedema, its potential as a diagnostic tool for lymphedema is limited 12 .
The strengths of this work come from the study's longitudinal and prospective design as well as its assessment of a population-based sample of women generally representative of the grade, stage and estrogen-receptor status, which range from 1.5-1.9 25 . Hence, we believe the results observed in this study are sufficiently robust to support a continued concern regarding a role for lymphedema in survival following breast cancer.
As a first report of an association between lymphedema and subsequent mortality among women with breast cancer, these results must be interpreted with caution. 
